Home / Market News / $SYRE
benzinga Corporate Catalyst Impact 55/100 ● neutral

BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target

Oct 19, 2026, 5:09 PM UTC · Primary ticker $SYRE

BTIG analyst Julian Harrison has reiterated a Buy rating and a $121 price target for Spyre Therapeutics. This filing indicates continued analyst confidence in the company, which could provide some positive sentiment for investors.

BTIG analyst Julian Harrison reiterated a 'Buy' rating and maintained a $121 price target for Spyre Therapeutics (SYRE). This action signals continued confidence from a prominent analyst in the company's prospects. For traders, this could provide a short-term positive sentiment boost, potentially leading to some upward price movement or stability. While not a new catalyst, the reaffirmation of a strong price target can reinforce existing bullish theses and attract new investors. The long-term implication depends on whether the company's fundamentals align with the analyst's valuation, but in the short-term, it reduces uncertainty around analyst coverage. A key opportunity for traders is to observe if this reiteration leads to increased trading volume or a price bump.

$SYRE positive Analyst reiterates Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.